Eczema (atopic dermatitis) is a chronic inflammatory skin condition causing itchy, inflamed patches that can significantly disrupt sleep and quality of life. Research has accelerated rapidly, with several new drug classes now approved and more in trials — making this one of the most active areas in dermatology.
What's actually going on in research
Dupilumab, which blocks IL-4 and IL-13 signaling, transformed treatment for moderate-to-severe eczema and remains the reference point against which newer drugs are compared. JAK inhibitors targeting the itch and inflammation pathways are now available in topical and oral forms, and trials are expanding their use in different age groups. Tralokinumab and lebrikizumab offer additional IL-13-specific options, and combination approaches with allergen immunotherapy are being explored.
JAK inhibitors
Oral and topical JAK inhibitors block the intracellular signaling that drives itch and skin inflammation. Trials are testing them in children, in flare prevention, and in combination with biologics.
Next-generation biologics
Drugs targeting IL-13 specifically (tralokinumab, lebrikizumab) or broader Th2 pathways are being compared head-to-head with dupilumab to find the best match for different patient profiles.
Allergen immunotherapy
Trials are testing whether structured allergen desensitization alongside biologic therapy reduces eczema severity in patients with documented environmental or food allergen sensitivities.
What to know before you search
Eligibility typically requires moderate-to-severe eczema by EASI or IGA score, inadequate response to topical treatments, and sometimes specific IgE or biomarker levels.
What types of trials are currently open
- Drug trials — Testing new biologics, JAK inhibitors, or topical agents for moderate-to-severe atopic dermatitis.
- Pediatric trials — Evaluating safety and dosing of newer treatments specifically in infants, children, and adolescents.
- Prevention trials — Testing early skin barrier interventions and emollient use in high-risk newborns to prevent eczema development.
- Comorbidity trials — Studying whether treating eczema reduces the atopic march to asthma and allergic rhinitis.
- Behavioral trials — Testing itch-scratch cycle interventions, habit reversal training, and sleep improvement programs.
Recently added Eczema trials
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage. While researchers know that the immune system is overactive in AD, it is difficult to measure the exact level of "damage" or "inflammation" happening deep within the skin using only a physical exam. The Purpose of This Study This study investigates a specific "danger signal" called circulating cell-free DNA (cfDNA). When skin cells are damaged or die due to inflammation, they release tiny fragments of DNA into the bloodstream. We believe these fragments might act as a trigger for the immune system, worsening the disease. What the Study Involves Researchers will collect blood samples and small skin biopsies from patients with AD and healthy volunteers. The study aims to: Compare the levels of cfDNA in the blood of AD patients versus healthy individuals. Determine if higher levels of cfDNA correlate with more severe skin symptoms (measured by scores like SCORAD and EASI). Examine how immune cells in the skin (macrophages) respond to these DNA fragments through a specific biological switch called the STING pathway. Potential Impact By understanding this "damage-signal" loop, this research may lead to new ways for doctors to monitor AD severity through simple blood tests and could identify new targets for future anti-inflammatory treatments.
Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Tralokinumab is a fully human anti-IL-13 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation. The aim of this study is to evaluate by RCM skin modifications of AD patients treated with tralokinumab.
Find Eczema trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.